Active Pharmaceutical Ingredients CDMO Market was valued at USD 118.2 Bn in 2023 and is expected to reach USD 190.11 Bn by 2030, at a CAGR of 7.06 % during the forecast period.Definition:
Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) refers to a specific type of company within the pharmaceutical industry. Active Pharmaceutical Ingredients CDMO deals with the manufacturing and development of active pharmaceutical ingredients and the outsourcing of services. Active pharmaceutical ingredients (APIs) are components of the global pharmaceutical supply chain. CDMOs play a central role in the production of medicines.Active Pharmaceutical Ingredients CDMO Market Overview:
Previously, active pharmaceutical ingredients were manufactured by pharmaceutical companies in countries like United States or United Kingdom. In the mid-1990s, the United States, Europe, and Japan produced 90% of the world’s active pharmaceutical ingredients. The recent growth of the global biopharmaceutical industry has contributed to increased active pharmaceutical ingredients manufacturing from other sources, mainly in low-cost labor markets such as China and India. Currently, contract development and manufacturing organization have formed them as best substitute for in-house development and manufacturing units of pharmaceutical companies. PCAS in France and Finland, Chemie Uetikon in Germany, PCI Synthesis in the United States and Wavelength in Israel & India have joined forces as Seqens CDMO to offer world-class drug Substance development and manufacturing services.To know about the Research Methodology :- Request Free Sample Report Drug research and development activities, high frequency of chronic diseases are expected to drive the growth of active pharmaceutical ingredients CDMO Market. The biopharmaceutical sector has gained a lot of attention in the healthcare sector and is expected to eyewitness significant growth during the forecast period. A contract development and manufacturing company (CDMO) is responsible to offers drug development and manufacturing services. Pharmaceutical companies are collaborating with CDMO as a way to outsource drug development and drug manufacturing. SK pharmtec is a global contract development and manufacturing organization (CDMO), and trusted partner concentrating in the manufacture of active pharmaceutical ingredients, intermediates, registered starting materials, and key building blocks for the pharmaceutical industry. The company is well-positioned to continue to play an important role in producing APIs in the U.S which ensures a robust domestic supply chain of high-quality pharmaceutical ingredients. Small biotechnology companies are hugely involved in contract manufacturing for manufacturing and outsourcing as CDMO being the convenient method for entering the market. Key players are forming robust footprints in the global active pharmaceutical ingredients CDMO market by Acquisitions and High investment in the pharmaceutical sector. In 2022, Pharmaron Beijing Co., Limited has acquired commercial API manufacturing facility in the United Kingdom from Recipharm. The acquisition has expanded Pharmaron's world-class chemistry and manufacturing services. In 2023, Cambrex has completed its $38 million capacity expansion in active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina. Recently, in 2024, Recipharm company has sold off seven of its manufacturing and development facilities in Europe to Blue Wolf Capital.
Active Pharmaceutical Ingredients CDMO Market Dynamics
An increase in investments in drug R&D is one of the key drivers in the Active Pharmaceutical Ingredients CDMO market. Rising R&D investments translate to a greater need for novel and complex drugs. Pharmaceutical companies are developing treatments for chronic diseases, personalized medicine approaches, and innovative therapies. The complexity is expected to encourage them to outsource API development and manufacturing to CDMOs with specialized expertise and resources. Pharmaceutical companies are looking for ways to streamline development processes and reduce costs. Partnering with CDMOs allows them to leverage existing infrastructure and expertise, potentially accelerating timelines and saving money. pharmaceutical companies can dedicate their internal resources to core competencies like drug discovery and clinical trials by outsourcing API development and manufacturing. It allows them to focus on their areas of strength while leveraging CDMOs for specialized tasks. An increase in R&D investment creates a ripple effect in the pharmaceutical industry, which is ultimately driving the growth of the Active Pharmaceutical Ingredients CDMO market. CDMO Active Pharmaceutical Ingredients Industry Is Undergoing a Transformation with A Focus on Integrated Services. The CDMO Active Pharmaceutical Ingredients industry is experiencing a significant shift towards integrated services. Historically, CDMOs primarily focused on manufacturing mature pharmaceuticals. They acted as external service providers, handling production after the development phase was complete. The pharmaceutical industry is witnessing a surge in demand for new and complex drugs, particularly biologics. Pharmaceutical companies are looking for ways to streamline development processes and reduce costs. Many CDMOs are expanding their offerings to include both development and manufacturing. CDMOs are acquiring new technologies and capabilities to handle complex API development and manufacturing processes. Some CDMOs are merging with other companies or acquiring smaller players to gain expertise in specific areas or expand geographically. A growing trend of CDMOs getting involved in earlier stages of drug development, collaboration with pharmaceutical companies on pre-clinical and clinical trials are expected to drive the active pharmaceutical ingredients CDMO market growth. The pharmaceutical companies can streamline the process by outsourcing both development and manufacturing to a single integrated CDMO. The integrated model opens doors to more comprehensive contracts and potentially leading to higher revenue streams for CDMOs. As the global population ages, the demand for treatments for chronic diseases increases, further driving R&D investment and the need for API CDMO services. New technologies in drug discovery and development require specialized expertise that CDMOs, which is making them valuable partners for pharmaceutical companies. The Increasing Outsourcing Trend in Pharmaceutical Represents Promising Opportunities For CDMO. The increasing outsourcing trend among pharmaceutical companies presents a wealth of promising opportunities for CDMOs. As pharmaceutical companies are shifting their focus towards scientific research and pharmaceutical marketing, CDMO are expected to establish themselves as vital partners and build integrated partnership with their customer. CDMOs can focus on their core strengths in development and manufacturing, allowing them to continuously improve their expertise and efficiency. Pharmaceutical companies can leverage the expertise and infrastructure of CDMOs, reducing their own capital expenditure and potentially mitigating risks associated with in-house development and manufacturing. The pharmaceutical companies are relying on CDMOs with specialized expertise in handling these challenging APIs. Active Pharmaceutical Ingredients CDMO Market Regulatory Landscape: The Active Pharmaceutical Ingredients (API) CDMO market is strongly regulated to ensure the safety, and efficacy of the drugs being developed and manufactured. International Council for Harmonisation is global organization sets guidelines for Good Manufacturing Practice (GMP) which ensure that APIs are consistently produced and controlled according to quality standards. US Food and Drug Administration (FDA) is FDA is responsible for regulating drugs in the United States and has its own set of cGMP regulations that CDMOs must comply with. European Medicines Agency (EMA) is the regulatory body for the European Union and has its own set of Good Manufacturing Practice (GMP) guidelines that CDMOs must follow. CDMOs that operate in multiple markets need to comply with the regulations of each market. The regulatory landscape is essential for ensuring the safety and efficacy of APIs.Active Pharmaceutical Ingredients CDMO Market Segment Analysis
Traditional Active Pharmaceutical Ingredient Segment is dominating the Active Pharmaceutical Ingredients CDMO Market. By Product Type, active pharmaceutical ingredients CDMO market is segmented into Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody-Drug Conjugate (ADC) and Other. Highly Potent Active Pharmaceutical Ingredients (HP-APIs) are potent drugs that can have a significant effect on the body at very low doses. It requires specialized facilities and stringent safety protocols during development and manufacturing. They often present greater challenges and require more specialized expertise from CDMOs, which is leading to potentially higher costs. Antibody-Drug Conjugates (ADCs) are complex biopharmaceutical drugs that combine a monoclonal antibody with a cytotoxic agent. ADCs are a rapidly growing segment because of their targeted approach to cancer treatment. It is expected to grow at a more than 9.55% rate of CAGR during the forecast period. Traditional active pharmaceutical ingredient segment held the dominant position in the global active pharmaceutical ingredients CDMO market with a share of 40.77% in 2023. Traditional Active Pharmaceutical Ingredients are well-established, small molecule drugs with a long history of safe and effective use. They are typically easier and less expensive to manufacture compared to newer types of APIs. The synthetic segment held the dominant position in the Active Pharmaceutical Ingredients CDMO Market. By Product Type, active pharmaceutical ingredients CDMO market is segmented into Synthetic and Biotech. Synthetic APIs are small molecule drugs created through chemical reactions in a lab or manufacturing facility. The starting materials are typically simple chemicals that are transformed step-by-step into the final drug molecule. The synthetic segment held the dominant position in active pharmaceutical ingredient CDMO market with a market share of 73.59% in 2023. The abundant availability of raw materials and flexibility offered by the molecule in synthesis are some of the prominent drivers behind the market growth. Moreover, various synthetic ingredients are expected to go off patent and also expected to create opportunities for the active pharmaceutical ingredients CDMO market players to invest in the market to generate more revenue during the forecast period. The biotech segment is growing at a high pace with a CAGR of 7.1% during the forecast period. The factors responsible for the growth of the market are amplified demand for higher molecular efficiency and the need for biopharmaceutical ingredients is likely to fuel the growth of the market during the forecast period.Innovative drug segment is gaining more attention in the Active Pharmaceutical Ingredient CDMO Market. The innovative drug segment is dominating the drug segment of the active pharmaceutical ingredient CDMO market with the largest market share of 73.09%. The strict rules and regulations imposed by the government authorizations and the approvals for the clinical trials together with the manufacturing of new molecules are expected to drive need for innovative drug segment. Further, rising R & D activities are boosting the growth of new molecules approvals. An innovation of unique molecules with better pharmacological actions are expected to drive the growth of the market during the forecast period. A generic drug is growing at a CAGR of 8.9% in the forecast period and the low cost of generic drugs and similar pharmacological action as compared to branded drugs are anticipated to shift the preference of consumers in the forecast period. Many pharmaceutical companies have a strong pipeline of innovative drugs in various stages of development, which ensures a consistent demand for innovative drug CDMO services. Pharmaceutical companies are investing heavily in R&D, leading to a surge in innovative drug development. Governments around the world are providing incentives for the development of innovative drugs. The Clinical segment is expected to grow at a 7.85% rate of CAGR during the forecast period. By workflow, active pharmaceutical ingredients CDMO market is segmented into clinical and commercial. Currently, commercial segment held the dominant position with a share of 60.49%. Commercial manufacturing involves producing APIs for large-scale drug production that is translating into a much higher volume compared to clinical trials. The market for commercially available drugs is significantly larger and more mature than the market for clinical trial drugs. The clinical segment plays a crucial role in the early stages of drug development. CDMOs provide support for manufacturing APIs for clinical trials, which are essential for testing the safety and efficacy of new drugs. The clinical segment is expected to grow at a 7.85% rate of CAGR during the forecast period. Oncology segment is emerging as New Trend of Application in the Active Pharmaceutical Ingredients CDMO Market. Oncology segment held the leading position in the active pharmaceutical ingredient CDMO market with share of 36.29% in 2023. An innovative cancer therapies and the growing prevalence of cancer all over the globe are expected to drive the demand for oncology drugs and treatments. The global burden of cancer translates to a constant demand for new and effective cancer therapies, driving growth in the oncology active pharmaceutical ingredient CDMO market. Advancements in cancer research are leading to the development of more targeted and personalized therapies. It requires complex APIs, which is expected to opportunity for CDMOs with expertise in handling specialized molecules. The cancer prevalence, rising healthcare spending, and growing adoption of new therapies are some of the primary driving factors, which are expected to boost the market growth during the forecast period. Active Pharmaceutical Ingredients CDMO Market Regional Insight The Asia Pacific region is projected to be leading region in the Global Active Pharmaceutical Ingredients CDMO Market. Contract Development and Manufacturing Organisation (CDMO) has emerged as a viable model for Asia Pacific Active Pharmaceutical Ingredients CDMO Market. Pharmaceutical companies are partnering with manufacturers in the emerging countries because of the availability of skilled, low-cost manpower and quality data. Cost-cutting, chasing innovation, gaining access to specialised knowledge and technology. CDMOs have seen significant acceptance in the industry with globalisation and focus of large players on cutting costs and optimising operations. The Asia Pacific region, mainly China and India is expected to be leading growth market in the active pharmaceutical ingredients CDMO industry because of India Active Pharmaceutical Ingredients CDMO Market Overview. The developing economies have established themselves as the major suppliers of API manufacturing service. The supply chains for active pharmaceutical ingredients are constantly evolving according to demand-supply trend in the industry. Price and regulatory compliances are also one of the key elements that affects active pharmaceutical ingredients industry. United States remains the primary hub for Active Pharmaceutical Ingredients CDMO. The US has a robust ecosystem for research and development in active pharmaceutical ingredients CDMO development, which decodes to a wider range of complex molecules being developed and manufactured in the US. The US Food and Drug Administration (FDA) has a well-established and rigorous regulatory framework for APIs, which ensures a high level of quality and safety for APIs manufactured in the US, which is a major advantage for pharmaceutical companies worldwide. The US has a long history of pharmaceutical manufacturing and a well-developed infrastructure for API CDMO services. The US is expected to maintain its leadership position in terms of innovation and high-value active pharmaceutical ingredients. Active Pharmaceutical Ingredients CDMO Market Predicted Key Findings: 1. Active Pharmaceutical Ingredients CDMO manufacturing footprints are expected to change significantly in response to increase labour costs, geopolitical challenges and requirement for greater supply chain resilience. 2. Active Pharmaceutical Ingredients CDMO Industry is expected to expand along the value chain into development in securing highmargin work and follow-on commercial revenues by 2030. 3. Many CDMO companies are expected to expand their production in India because of given trade barriers and rising labour costs in China. 4. CDMO footprints are expected to establish facilities in India, Thailand and Vietnam to take advantage of competitive labour rates with managing rising geopolitical tensions between the US and China. Active Pharmaceutical Ingredients CDMO Market Recent Developments: In 2023, Piramal Pharma Solutions, who is a Contract Development and Manufacturing Organization (CDMO) has announced that it has begun production of active pharmaceutical ingredients at its facility in Riverview. The company is offering end-to-end development and manufacturing solutions across the drug life cycle and serve customers through a globally integrated network of facilities in North America, Europe, and Asia. In 2022, EUROAPI has announced an initial €18 million investment for the installation of new state-of-the-art manufacturing equipment at its Frankfurt site. The company is expected to meet the growing Contract Development and Manufacturing Organization (CDMO) demand and focused on the debottlenecking of the current capacity with the objective of increasing EUROAPI’s peptide and oligonucleotide output to circa 500 kilograms per year by 2025.
Active Pharmaceutical Ingredients CDMO Market Scope: Inquire before buying
Active Pharmaceutical Ingredients CDMO Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 118.2 Bn. Forecast Period 2024 to 2030 CAGR: 7.06% Market Size in 2030: US $ 190.11 Bn. Segments Covered: by Product Type Traditional Active Pharmaceutical Ingredient (Traditional API) Highly Potent Active Pharmaceutical Ingredient (HP-API) Antibody-Drug Conjugate (ADC) Other by Drug Synthetic Biotech by Synthesis Innovative Generic by Workflow Clinical Commercial by Application Oncology Hormonal Glaucoma Cardiovascular Diabetes Other Active Pharmaceutical Ingredients CDMO Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Leading Active Pharmaceutical Ingredients CDMO Key Players include:
1. 10x Genomics 2. Cambrex 3. Recipharm 4. Thermo Fisher Pantheon 5. Corden Pharma 6. Samsung Biologics 7. Lonza 8. Catalent 9. Siegfried 10. Piramal Pharma Solutions 11. Boehringer Ingelheim 12. catelent Inc. 13. Recipharm AB 14. Jubilant Life Science Ltd 15. Pathoeon Inc. 16. Olon 17. LGM Pharma 18. EUROAPI 19. Curia 20. Polypeptide FAQs: 1. What are the growth drivers for the Global Active Pharmaceutical Ingredients CDMO market? Ans. Rising Prevalence of Chronic Diseases, Increased R&D Activities in Pharma, Growing Adoption of Generic Drugs and Shifting Landscape to Outsourcing are some of the major factors driving the Global Active Pharmaceutical Ingredients CDMO market. 2. What are the factors restraining the global Active Pharmaceutical Ingredients CDMO market growth during the forecast period? Ans. Stringent Regulatory Requirements, Fluctuations in Raw Material Prices, Environmental Concerns are expected to be the major factors restraining the global Active Pharmaceutical Ingredients CDMO market growth during the forecast period. 3. Which region is expected to lead the global Active Pharmaceutical Ingredients CDMO market during the forecast period? Ans. Asia Pacific is expected to lead the global Active Pharmaceutical Ingredients CDMO market during the forecast period. 4. What is the projected market size and growth rate of the Global Active Pharmaceutical Ingredients CDMO Market? Ans. The Global Active Pharmaceutical Ingredients CDMO Market size was valued at USD 118.2 Billion in 2023 and the total Global Active Pharmaceutical Ingredients CDMO revenue is expected to grow at a CAGR of 7.06% from 2024 to 2030, reaching nearly USD 190.11 Billion by 2030. 5. What segments are covered in the Global Active Pharmaceutical Ingredients CDMO Market report? Ans. The segments covered in the Global Active Pharmaceutical Ingredients CDMO market report are Product Type, Drug, Synthesis, Workflow, Application, and Region.
1. Active Pharmaceutical Ingredients CDMO Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Active Pharmaceutical Ingredients CDMO Market: Dynamics 2.1. Active Pharmaceutical Ingredients CDMO Market Trends by Region 2.1.1. Global Active Pharmaceutical Ingredients CDMO Market Trends 2.1.2. North America Active Pharmaceutical Ingredients CDMO Market Trends 2.1.3. Europe Active Pharmaceutical Ingredients CDMO Market Trends 2.1.4. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Trends 2.1.5. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Trends 2.1.6. South America Active Pharmaceutical Ingredients CDMO Market Trends 2.2. Active Pharmaceutical Ingredients CDMO Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Active Pharmaceutical Ingredients CDMO Market Drivers 2.2.1.2. North America Active Pharmaceutical Ingredients CDMO Market Restraints 2.2.1.3. North America Active Pharmaceutical Ingredients CDMO Market Opportunities 2.2.1.4. North America Active Pharmaceutical Ingredients CDMO Market Challenges 2.2.2. Europe 2.2.2.1. Europe Active Pharmaceutical Ingredients CDMO Market Drivers 2.2.2.2. Europe Active Pharmaceutical Ingredients CDMO Market Restraints 2.2.2.3. Europe Active Pharmaceutical Ingredients CDMO Market Opportunities 2.2.2.4. Europe Active Pharmaceutical Ingredients CDMO Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Drivers 2.2.3.2. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Restraints 2.2.3.3. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Opportunities 2.2.3.4. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Drivers 2.2.4.2. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Restraints 2.2.4.3. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Opportunities 2.2.4.4. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Challenges 2.2.5. South America 2.2.5.1. South America Active Pharmaceutical Ingredients CDMO Market Drivers 2.2.5.2. South America Active Pharmaceutical Ingredients CDMO Market Restraints 2.2.5.3. South America Active Pharmaceutical Ingredients CDMO Market Opportunities 2.2.5.4. South America Active Pharmaceutical Ingredients CDMO Market Challenges 2.3. PORTER’s Five Power Sources Analysis 2.4. PESTLE Analysis 2.5. Value Chain Analysis 2.6. Regulatory Landscape by Region 2.6.1. Global 2.6.2. North America 2.6.3. Europe 2.6.4. Asia Pacific 2.6.5. Middle East and Africa 2.6.6. South America 2.7. Key Opinion Leader Analysis for Active Pharmaceutical Ingredients CDMO Market Application 2.8. Analysis of Government Schemes and Initiatives for Active Pharmaceutical Ingredients CDMO Market Application 2.9. The Global Pandemic Impact on Active Pharmaceutical Ingredients CDMO Market 2.10. Active Pharmaceutical Ingredients CDMO Market Price Trend Analysis (2022-23) 3. Active Pharmaceutical Ingredients CDMO Market: Global Market Size and Forecast by Segmentation (by Value) (2023-2030) 3.1. Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 3.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 3.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 3.1.3. Antibody-Drug Conjugate (ADC) 3.1.4. Other 3.2. Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 3.2.1. Synthetic 3.2.2. Biotech 3.3. Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 3.3.1. Innovative 3.3.2. Generic 3.4. Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 3.4.1.1. Clinical 3.4.1.2. Commercial 3.5. Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 3.5.1.1. Oncology 3.5.1.2. Hormonal 3.5.1.3. Glaucoma 3.5.1.4. Cardiovascular 3.5.1.5. Diabetes 3.5.1.6. Other 3.6. Active Pharmaceutical Ingredients CDMO Market Size and Forecast, by region (2023-2030) 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 4. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 4.1. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 4.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 4.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 4.1.3. Antibody-Drug Conjugate (ADC) 4.1.4. Other 4.2. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 4.2.1. Synthetic 4.2.2. Biotech 4.3. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 4.3.1. Innovative 4.3.2. Generic 4.4. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 4.4.1. Clinical 4.4.2. Commercial 4.5. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 4.5.1.1. Oncology 4.5.1.2. Hormonal 4.5.1.3. Glaucoma 4.5.1.4. Cardiovascular 4.5.1.5. Diabetes 4.5.1.6. Other 4.6. North America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, by Country (2023-2030) 4.6.1. United States 4.6.1.1. United States Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 4.6.1.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 4.6.1.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 4.6.1.1.3. Antibody-Drug Conjugate (ADC) 4.6.1.1.4. Other 4.6.1.2. United States Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 4.6.1.2.1. Synthetic 4.6.1.2.2. Biotech 4.6.1.3. United States Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 4.6.1.3.1. Innovative 4.6.1.3.2. Generic 4.6.1.4. United States Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 4.6.1.4.1.1. Clinical 4.6.1.4.1.2. Commercial 4.6.1.5. United State Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 4.6.1.5.1.1. Oncology 4.6.1.5.1.2. Hormonal 4.6.1.5.1.3. Glaucoma 4.6.1.5.1.4. Cardiovascular 4.6.1.5.1.5. Diabetes 4.6.1.5.1.6. Other 4.6.2. Canada 4.6.2.1. Canada Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 4.6.2.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 4.6.2.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 4.6.2.1.3. Antibody-Drug Conjugate (ADC) 4.6.2.1.4. Other 4.6.2.2. Canada Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 4.6.2.2.1. Synthetic 4.6.2.2.2. Biotech 4.6.2.3. Canada Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 4.6.2.3.1. Innovative 4.6.2.3.2. Generic 4.6.2.4. Canada Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 4.6.2.4.1.1. Clinical 4.6.2.4.1.2. Commercial 4.6.2.5. Canada Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 4.6.2.5.1.1. Oncology 4.6.2.5.1.2. Hormonal 4.6.2.5.1.3. Glaucoma 4.6.2.5.1.4. Cardiovascular 4.6.2.5.1.5. Diabetes 4.6.2.5.1.6. Other 4.6.3. Mexico 4.6.3.1. Mexico Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 4.6.3.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 4.6.3.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 4.6.3.1.3. Antibody-Drug Conjugate (ADC) 4.6.3.1.4. Other 4.6.3.2. Mexico Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 4.6.3.2.1. Synthetic 4.6.3.2.2. Biotech 4.6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 4.6.3.3.1. Innovative 4.6.3.3.2. Generic 4.6.3.4. Mexico Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 4.6.3.4.1.1. Clinical 4.6.3.4.1.2. Commercial 4.6.3.5. Mexico Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 4.6.3.5.1.1. Oncology 4.6.3.5.1.2. Hormonal 4.6.3.5.1.3. Glaucoma 4.6.3.5.1.4. Cardiovascular 4.6.3.5.1.5. Diabetes 4.6.3.5.1.6. Other 5. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 5.1. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.2. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.3. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.4. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.5. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, by Country (2023-2030) 5.6.1. United Kingdom 5.6.1.1. United Kingdom Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.1.2. United Kingdom Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.1.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.1.4. United Kingdom Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.1.5. United Kingdom Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.2. France 5.6.2.1. France Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.2.2. France Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.2.3. France Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.2.4. France Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.2.5. France Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.3. Germany 5.6.3.1. Germany Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.3.2. Germany Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.3.3. Germany Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.3.4. Germany Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.3.5. Germany Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.3.6. 5.6.4. Italy 5.6.4.1. Italy Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.4.2. Italy Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.4.3. Italy Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.4.4. Italy Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.4.5. Italy Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.5. Spain 5.6.5.1. Spain Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.5.2. Spain Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.5.3. Spain Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.5.4. Spain Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.5.5. Spain Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.6. Sweden 5.6.6.1. Sweden Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.6.2. Sweden Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.6.3. Sweden Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.6.4. Sweden Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.6.5. Sweden Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.7. Austria 5.6.7.1. Austria Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.7.2. Austria Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.7.3. Austria Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.7.4. Austria Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.7.5. Austria Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 5.6.8. Rest of Europe 5.6.8.1. Rest of Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 5.6.8.2. Rest of Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 5.6.8.3. Rest of Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 5.6.8.4. Rest of Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 5.6.8.5. Rest Of Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 6.1. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.2. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.3. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.4. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.5. Europe Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, by Country (2023-2030) 6.6.1. China 6.6.1.1. China Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.1.2. China Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.1.3. China Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.1.4. China Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.1.5. China Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.2. S Korea 6.6.2.1. S Korea Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.2.2. S Korea Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.2.3. S Korea Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.2.4. S Korea Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.2.5. S korea Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.3. Japan 6.6.3.1. Japan Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.3.2. Japan Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.3.4. Japan Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.3.5. Japan Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.4. India 6.6.4.1. India Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.4.2. India Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.4.3. India Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.4.4. India Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.4.5. India Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.5. Australia 6.6.5.1. Australia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.5.2. Australia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.5.3. Australia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.5.4. Australia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.5.5. Australia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.6. Indonesia 6.6.6.1. Indonesia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.6.2. Indonesia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.6.3. Indonesia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.6.4. Indonesia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.6.5. Indonesia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.7. Malaysia 6.6.7.1. Malaysia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.7.2. Malaysia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.7.3. Malaysia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.7.4. Malaysia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.7.5. Malaysia Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 6.6.8. Rest of Asia Pacific 6.6.8.1. Rest of Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 6.6.8.2. Rest of Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 6.6.8.3. Rest of Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 6.6.8.4. Rest of Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 6.6.8.5. Rest of Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 7. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030 7.1. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 7.2. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 7.3. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 7.4. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 7.5. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 7.6. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, by Country (2023-2030) 7.6.1. South Africa 7.6.1.1. South Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 7.6.1.2. South Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 7.6.1.3. South Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 7.6.1.4. South Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 7.6.1.5. South Africa Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 7.6.2. GCC 7.6.2.1. GCC Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 7.6.2.2. GCC Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 7.6.2.3. GCC Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 7.6.2.4. GCC Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 7.6.2.5. GCC Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 7.6.3. Rest of ME&A 7.6.3.1. Rest of ME&A Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 7.6.3.2. Rest of ME&A Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 7.6.3.3. Rest of ME&A Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 7.6.3.4. Rest of ME&A Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 7.6.3.5. Rest of ME&A Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 8. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030 8.1. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 8.2. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 8.3. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 8.4. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 8.5. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 8.6. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By End User (2023-2030) 8.7. South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, by Country (2023-2030) 8.7.1. Brazil 8.7.1.1. Brazil Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 8.7.1.2. Brazil Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 8.7.1.3. Brazil Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 8.7.1.4. Brazil Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 8.7.1.5. Brazil Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 8.7.2. Argentina 8.7.2.1. Argentina Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 8.7.2.2. Argentina Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 8.7.2.3. Argentina Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 8.7.2.4. Argentina Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 8.7.2.5. Argentina Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 8.7.3. Rest Of South America 8.7.3.1. Rest Of South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Product Type (2023-2030) 8.7.3.2. Rest Of South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Drug (2023-2030) 8.7.3.3. Rest Of South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Synthesis (2023-2030) 8.7.3.4. Rest of South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Workflow (2023-2030) 8.7.3.5. Rest of South America Active Pharmaceutical Ingredients CDMO Market Size and Forecast, By Application (2023-2030) 9. Global Active Pharmaceutical Ingredients CDMO Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Product Segment 9.3.3. End-user Segment 9.3.4. Revenue (2023) 9.4. Leading Active Pharmaceutical Ingredients CDMO Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. 10x Genomics 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Recent Developments 10.2. Cambrex Corporation 10.3. Recipharm AB 10.4. Thermo Fisher Scientifi 10.5. CordenPharma International 10.6. Samsung Biologics 10.7. Lonza Group 10.8. Catalent, Inc. 10.9. Siegfried Holding AG 10.10. Piramal Pharma Solutions 10.11. Boehringer Ingelheim 10.12. catelent Inc. 10.13. Recipharm AB 10.14. Jubilant Life Science Ltd 10.15. Pathoeon Inc. 10.16. Olon 10.17. LGM Pharma 10.18. EUROAPI 10.19. Curia 10.20. Polypeptide 11. Key Findings 12. Application Recommendations 13. Active Pharmaceutical Ingredients CDMO Market: Research Methodology 14. Terms and Glossary